

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Melatonin Unimedic Pharma 1 mg/ml oral solution.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml oral solution contains 1 mg melatonin.

Excipients with known effect

1 ml oral solution contains 1 mg of methyl parahydroxybenzoate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution.

Clear colorless to yellow solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Melatonin Unimedic Pharma is indicated for:

- Short-term treatment of jet lag in adults.
The medicinal product is recommended to adult travelers flying across ≥ 5 time zones, particularly in an easterly direction, and especially if they have experienced jet lag symptoms on previous journeys. Travelers crossing 2-4 time zones can also use it if need be.
- Sleep onset insomnia in children and adolescents aged 6-17 years with ADHD, where sleep hygiene measures have been insufficient

4.2 Posology and method of administration

Posology

Adults with jet lag

The recommended dose is 1-5 mg one hour before bedtime at destination.

Recommended starting dose:

2 ml (equivalent to 2 mg)

Due to the potential for incorrectly timed intake of melatonin to have no effect, or an adverse effect, on re-synchronisation following jet lag, Melatonin Unimedic Pharma oral solution should not be taken before 20:00 hr. or after 04:00 hr. at destination.

Maximal recommended daily dose:

5 ml (equivalent to 5 mg) for a maximum of 5 days.

A maximum of 16 treatment cycles may occur per year.

Padiatric population with ADHD

Treatment should be initiated by physicians experienced in ADHD and/or paediatric sleep medicine. When treating insomnia in children and adolescents, melatonin should only be administered after other treatable causes of insomnia have been ruled out by appropriate specialist investigation and non-pharmacological measures have been insufficient.

Recommended starting dose:

1-2 ml (equivalent to 1-2 mg) 30 to 60 minutes before bedtime.

The dose should be adjusted individually to a maximum of 5 ml (equivalent to 5 mg) daily regardless of age. The lowest effective dose should be sought.

Maximal recommended daily dose:

5 ml (equivalent to 5 mg)

Limited data are available for up to 3 years of treatment. After at least 3 months of treatment, the physician should evaluate the treatment effect and consider stopping treatment if no clinically relevant treatment effect is seen. The patient should be monitored at regular intervals (at least every 6 months) to check that Melatonin Unimedica Pharma is still the most appropriate treatment. During ongoing treatment, especially if the treatment effect is uncertain, discontinuation attempts should be done regularly, e.g. once per year.

If the sleep disorder has started during treatment with medicinal products for ADHD, dose adjustment or switching to another product should be considered.

Special populations

Elderly

As the pharmacokinetics of melatonin (immediate release) is comparable in young adults and elderly persons in general, no specific dosage recommendations for elderly persons are provided (see section 5.2).

Renal impairment

The effect of any degree of renal impairment on the pharmacokinetics of melatonin has not been studied. Published data show elevated endogenous melatonin levels in patients with chronic renal failure. Caution should therefore be exercised when administering melatonin to patients with renal impairment (see section 5.2).

Hepatic impairment

There are no known studies on the use of melatonin in patients with hepatic impairment. Published data show markedly elevated endogenous melatonin levels in patients with hepatic impairment. Therefore, Melatonin Unimedica Pharma is not recommended for patients with hepatic impairment (see section 5.2).

Pediatric population

The efficacy and safety of melatonin for use in children with ADHD have not been established in children under 6 years.

The efficacy and safety of melatonin for use in jet-lag have not been established in children under 18 years.

Method of administration

Oral use.

Melatonin should be taken at least 2 hours before and at least 2 hours after a meal; ideally at least 3 hours after meal by persons with significantly impaired glucose tolerance or diabetes (see section 4.4).

A measuring device, an oral syringe, is packed together with the oral liquid dosage form. The capacity of the syringe is 5 ml with scale graduation of 0.2 ml.

Instruction for use

1. Remove the bottle cap.
2. Insert the syringe into the hole of the integrated adapter in the bottle opening and turn the bottle upside down. Measure the dose by slowly pulling out the plunger to the correct volume. Read the dose on the top of the piston. Turn the bottle right and remove the syringe.
3. The child should sit upright. Aim the tip of the syringe at the inside of the cheek. Slowly push in the plunger and allow the child to swallow naturally. Too fast administration of the medicine into the throat can cause discomfort.
4. Clean the inside of the syringe after each use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Possible long-term effects of melatonin have been inadequately studied. There are theoretical risks based on biological effects of melatonin, e.g. immunological regulation, effects on the threshold for seizures and endocrinological effects, which could affect puberty development and fertility, respectively.

Epilepsy

Caution when used in people with epilepsy, as melatonin has been reported to both increase and decrease the frequency of seizures.

Immunological diseases

Occasional case reports have described exacerbation of an autoimmune disease in patients taking melatonin. There are no data regarding use of melatonin in patients with autoimmune diseases. Melatonin are not recommended in patients with autoimmune diseases.

Drowsiness

Melatonin can cause drowsiness. Therefore, the drug should be used with caution if it is likely that the drowsiness may be associated with a safety risk.

Diabetes

Limited data suggest that melatonin taken in close proximity to ingestion of carbohydrate-rich meals may impair blood glucose control for several hours. Melatonin should be taken at least 2 hours before and at least 2 hours after a meal; ideally at least 3 hours after meal by persons with significantly impaired glucose tolerance or diabetes.

This medicine contains methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).

This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults. Melatonin is metabolized mainly via the enzyme CYP1A2. Therefore, interactions between melatonin and other active substances as a consequence of their effect on CYP1A enzymes are possible.

Pharmacokinetic interactions

Agents that can increase plasma concentrations of melatonin

CYP 1A inhibitors

Co-administration of melatonin with CYP1A2 inhibitors, such as fluvoxamine, quinolones, cimetidine,

and 5- and 8-methoxypsoralen (5- and 8-MOP), may lead to increased melatonin exposure through inhibition of melatonin metabolism.

Fluvoxamine

Fluvoxamine is a potent inhibitor of CYP1A2 and to a lesser extent CYP2C. Fluvoxamine has been shown to increase serum concentrations of orally administered melatonin (17-fold higher AUC and 12-fold higher C_{max}). The combination should be avoided.

Cimetidine

Cimetidine is a weak inhibitor of CYP1A2. Cimetidine has been reported to increase plasma concentrations of melatonin. Caution should be exercised in patients treated with cimetidine.

Estrogens

Estrogens have been shown to increase melatonin concentrations by inhibiting CYP1A1 and CYP1A2 (4-5 fold increase in melatonin concentrations when used in combination with combined hormonal contraceptives). Caution must be exercised in patients treated with estrogens (e.g. hormonal contraceptives or hormonal substitution therapy).

Caffeine

Caffeine is a substrate for CYP1A2. Caffeine has been shown to increase serum concentrations of orally administered melatonin (2.2-fold higher AUC and 2.4-fold higher C_{max}).

Agents that can decrease plasma concentrations of melatonin

CYP1A inducers

Co-administration of melatonin with CYP1A2 inducers, such as carbamazepine, rifampicin and phenytoin, may result in reduced melatonin exposure through an increase in melatonin metabolism. Dose adjustment may be needed.

Smoking

The metabolism of melatonin may be induced by smoking, which may lead to reduced melatonin concentrations. The melatonin AUC were significantly lower during smoking compared to after smoking abstinence (2.9-fold lower AUC).

Pharmacodynamic interactions

Adrenergic agonists / antagonists, opiate agonists / antagonists, antidepressants, prostaglandin inhibitors, tryptophan and alcohol affect the endogenous secretion of melatonin in the epiphysis. Whether these interactions are of clinical significance is unknown.

Alcohol

Alcohol should not be taken with melatonin as it may reduce the effect of melatonin on sleep.

Benzodiazepine-like hypnotics

Melatonin may enhance the sedative properties of benzodiazepine and non-benzodiazepine hypnotics such as zaleplon, zolpidem and zopiclone. In a clinical study, there was clear evidence of a transient pharmacodynamic interaction between melatonin prolonged-release tablet and zolpidem one hour after concomitant dosing. Concomitant administration led to an increased reduction in attention, memory and coordination compared to zolpidem alone.

Nifedipine

Melatonin may reduce the hypotensive effect of nifedipine, so caution should be exercised in this combination and dose adjustment of nifedipine may be needed.

Warfarin

Case reports have reported that patients treated with melatonin and warfarin received concurrent changes in INR and prothrombin time. The combination of warfarin or other vitamin K antagonists with melatonin may require dose adjustment of the anticoagulant drugs and should be avoided.

Thioridazine/Imipramine

Melatonin may enhance the feelings of drowsiness and inability to perform tasks when administered with thioridazine or imipramine.

Beta-blockers

Beta-blockers may suppress the endogenous melatonin but the clinical relevance of this is unknown when administering exogenous melatonin.

NSAIDs

Some NSAIDs, e.g. aspirin, ibuprofen, may reduce the endogenous secretion of melatonin, but the clinical relevance of this is unknown when administering exogenous melatonin.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data for the use of melatonin in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Exogenous melatonin readily crosses the human placenta Melatonin Unimedic Pharma is not recommended during pregnancy or in women and adolescents of childbearing potential not using contraception.

Breast-feeding

There is insufficient data on the excretion of melatonin/metabolites in human milk. Endogenous melatonin was measured in human breast milk thus exogenous melatonin is probably secreted into human milk. A risk for the breast-fed child cannot be excluded. Melatonin Unimedic Pharma should not be used during breast-feeding.

Fertility

There is limited clinical data about effects of melatonin on fertility. Animal studies are insufficient with respect to effects on fertility.

4.7 Effects on ability to drive and use machines

Melatonin has moderate effect on the ability to drive and use machines. Melatonin may cause drowsiness; therefore, the product should be used with caution if the effects of drowsiness are likely to be associated with a risk to safety.

4.8 Undesirable effects

Melatonin causes few and no serious adverse reactions in the short term, up to three months. There is limited documentation of long-term treatment with melatonin. Reported adverse reactions are mainly fatigue, dizziness and headache. However, these side effects are also common for placebo-treated patients.

Tabulated risks of adverse reactions

In the table below all adverse reactions are listed according to organ class and frequency: Very common ($\geq 1/10$), Common (≥ 100 , $< 1/10$), Uncommon ($\geq 1/1000$, $< 1/100$), Rare ($\geq 1/10\ 000$, $< 1/1000$), Very rare ($< 1/10\ 000$), Not known (cannot be estimated from the available data).

Adverse reactions are presented within each frequency in order of decreasing seriousness.

Table 1		
System organ class	Frequency	Adverse reaction
Infections and infestations	Rare	Herpes Zoster

Blood and lymphatic system disorders	Rare	Leukopenia, thrombocytopenia
Immune system disorders	Not known	Hypersensitivity reaction
Metabolism and nutrition disorders	Rare	Hypertriglyceridemia, hypocalcemia, hyponatremia
Psychiatric disorders	Uncommon	Irritability, nervousness, restlessness, insomnia, abnormal dreams, nightmares, anxiety
	Rare	Mood altered, aggression, agitation, crying, stress symptoms, disorientation, early morning awakening, libido increased, depressed mood, depression
Nervous system disorders	Common	Headache, somnolence
	Uncommon	Migraine, lethargy, psychomotor hyperactivity, dizziness
	Rare	Syncope, memory impairment, disturbance in attention, dreamy state, restless legs syndrome, poor quality sleep, paresthesia
Eyes	Rare	Visual acuity reduced, vision blurred, lacrimation increased
Ear and labyrinth disorders	Rare	Vertigo positional, vertigo
Cardiac disorders	Rare	Angina pectoris, palpitations
Vascular disorders	Uncommon	Hypertension
	Rare	Hot flush
Gastrointestinal disorders	Uncommon	Abdominal pain, abdominal pain upper, dyspepsia, mouth ulceration, dry mouth, nausea
	Rare	Gastro-esophageal reflux disease, gastrointestinal disorder, oral mucosal blistering, tongue ulceration, gastrointestinal upset, vomiting, bowel sounds abnormal, flatulence, salivary hypersecretion, halitosis, abdominal discomfort, gastric disorder, gastritis
Hepatobiliary disorders	Uncommon	Hyperbilirubinemia
Skin and subcutaneous tissue disorders	Uncommon	Dermatitis, night sweats, pruritus, rash, pruritus generalised, dry skin
	Rare	Eczema, erythema, hand dermatitis, psoriasis, rash generalised, rash pruritic, nail disorder
	Not known	Angioedema, oedema of mouth, tongue oedema
Musculoskeletal and connective tissue disorders	Uncommon	Pain in extremity
	Rare	Arthritis, muscle spasms, neck pain, night cramps
	Uncommon	Glycosuria, proteinuria

Renal and urinary disorders	Rare	Polyuria, hematuria, nocturia
Reproductive system and breast disorders	Uncommon	Menopausal symptoms
	Rare	Priapism, prostatitis
	Not known	Galactorrhea
General disorders and administration site conditions	Uncommon	Asthenia, chest pain
	Rare	Fatigue, pain, thirst
Investigations	Uncommon	Liver function test abnormal, weight increased
	Rare	Hepatic enzyme increased, blood electrolytes abnormal, laboratory test abnormal

Pediatric population

In the pediatric population a low frequency of generally mild adverse reactions has been reported. The adverse events have not been significantly different in children who has received placebo compared to children who received melatonin. The most common adverse effects were headache, hyperactivity, vertigo and abdominal pain. No serious adverse effects have been observed.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Administration of repeated daily doses of up to 300 mg melatonin without any clinically significant side effects has been reported in the literature.

Drowsiness can be expected in case of overdose. Due to the short half-life of melatonin, complete elimination of melatonin from the body is expected within 12 hours of ingestion. Physicians should assess whether common overdose measures should be used.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Psycholeptics, melatonin receptor agonists, ATC code: N05CH01.

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone produced by the epiphysis and structurally related to serotonin. Melatonin is involved in controlling the circadian rhythm and adaptation to the light-dark cycle. It is also associated with a sedative effect and an increased propensity for sleep.

Serum concentrations of endogenous melatonin vary over the day. Melatonin levels increase during the dark hours of the day with maximum serum concentrations between 02 and 04 in the morning (Srinivasan 2009; Tordjman 2017). Thereafter, serum levels of melatonin gradually decrease. Only a small amount of melatonin is excreted during the light hours of the day.

Mechanism of action

The activity of melatonin on MT1, MT2 and MT3 receptors is thought to contribute to its sleep-promoting properties since these receptors (especially MT1 and MT2) are involved in the regulation of diurnal rhythm and sleep regulation.

Pharmacodynamic effects

Melatonin has a hypnotic / sedative effect and increases propensity for sleep. Melatonin administered earlier or later than the nocturnal peak in melatonin secretion can, respectively, advance or delay the circadian rhythmicity of melatonin secretion. Administration of melatonin at bedtime (between 22:00 and 24:00 hr) at destination following rapid transmeridian travel (aircraft flight) hastens re-synchronisation of circadian rhythmicity from 'departure time' to 'destination time', and ameliorates the collection of symptoms known as jet lag that are a consequence of such de-synchronisation.

Clinical efficacy and safety

Typical symptoms of jet lag are sleep disturbances and daytime tiredness and fatigue, though mild cognitive impairment, irritability, and gastrointestinal disturbances may also occur.

Jet lag is worse the more time-zones crossed and is typically worse following eastward travel. Eight of ten clinical trials found that melatonin, taken close to the target bedtime at the destination (10 pm to midnight), decreased jet lag from flights crossing five or more time zones.

The benefit is likely to be greater the more time zones are crossed, and less for westward flights. Daily doses of melatonin between 0.5 and 5 mg are similarly effective, except that people fall asleep faster and sleep better after 5 mg than 0.5 mg.

Clinical trials have found melatonin to reduce patient-assessed overall symptoms of jet lag by ~44%, and to shorten the duration of jet lag. In 2 studies of flights over 12 time-zones melatonin effectively reduced the duration of jet lag by ~33%. Due to the potential for incorrectly timed intake of melatonin to have no effect, or to cause an adverse effect, on re-synchronisation of circadian rhythmicity/jet lag, melatonin should not be taken before 20:00 hr. or after 04:00 hr. at destination.

Adverse reactions reported in jet lag studies involving melatonin doses of 0.5 to 8 mg were typically mild, and often difficult to distinguish from symptoms of jet lag. Transient drowsiness/sedation, headache and dizziness/disorientation were reported; these same adverse reactions, plus nausea, are those typically associated with short-term use of melatonin in reviews of the safety of melatonin in humans.

Pediatric population

Melatonin treatment has been studied in a 4-week randomized, double-blind, placebo-controlled study conducted in 105 children between 6-12 years of age, with ADHD and chronic sleep onset insomnia (van der Heijden KB et al. 2007). Participants received melatonin (3 mg when body weight <40 kg [n = 44]; or 6 mg when body weight >40 kg [n = 9]) in fast-release tablets or placebo.

Mean actigraphic estimate of sleep onset advanced by 26.9 ± 47.8 minutes with melatonin, whereas there was a delay of 10.5 ± 37.4 minutes with placebo ($p < 0.0001$). 48.8% of children who received melatonin showed an advance of sleep onset >30 minutes compared to 12.8% with placebo ($p = 0.001$). There was an increase in mean total time asleep of 19.8 ± 61.9 minutes with melatonin and a decrease of 13.6 ± 50.6 minutes with placebo ($p = 0.01$). As compared with placebo, the melatonin group showed a decrease in sleep latency ($p = 0.001$) and increase in sleep efficiency ($p = 0.01$). The mean score on sleep log item difficulty falling asleep decreased by 1.2 ± 1.3 points (35.3% of baseline) with melatonin and by 0.1 ± 0.8 points (4.3% of baseline) with placebo ($p < 0.0001$).

There was no significant effect on behavior, cognition, and quality of life. There were no discontinuations or withdrawals caused by adverse events.

5.2 Pharmacokinetic properties

The pharmacokinetic parameters below are based on adult documentation.

Absorption

The absorption of oral melatonin is almost complete in adults. The bioavailability is 10–35% due to extensive first-pass metabolism of melatonin. Maximum concentration of orally administered

melatonin occurs after 15–90 minutes (median $T_{\max} = 52$ min). Based on limited data with high inter-subject variability, food intake may increase exposure and maximum plasma concentration of melatonin, likely not to a clinically relevant extent.

Distribution

Plasma protein binding of melatonin in vitro is approximately 60%. The mean volume of distribution is 1.2 and 1.8 L/kg (84 and 126 L for a 70 kg subject) for subjects receiving 10 mg and 0.5 µg/kg intravenous doses of melatonin respectively.

Biotransformation

Melatonin is mainly eliminated by hydroxylation to 6-hydroxymelatonin in the liver, primarily mediated by CYP1A2 (to a lesser extent by CYP1A1). Quantitatively less important is O-demethylation to N-acetyl-5-hydroxytryptamine mediated by CYP2C19. Melatonin metabolites are mainly eliminated by the urine, ~ 90% as sulphate and glucuronide conjugates of 6-hydroxymelatonin. Less than 1% of the melatonin dose is excreted unchanged in the urine.

Elimination

Melatonin has a short half-life ($t_{1/2}$) of between 30 and 60 minutes. The half-life, on average, is comparable or slightly shorter in children compared to adults.

Gender

Higher exposure and maximum plasma concentrations have been reported in women compared to men who have received melatonin orally, however a large variability in the pharmacokinetics is observed. Plasma melatonin half-life does not appear to be significantly different in men and women. Dose adjustment for women are not necessary.

Linearity

Maximum concentration and exposure of melatonin after oral dosing increases proportionally to the dose from 0.25 up to 10 mg.

Special patient groups

Renal impairment

The effect of renal impairment on the pharmacokinetics of melatonin administered has not been studied. However, published data show elevated endogenous melatonin levels in patients with chronic renal failure (see section 4.2).

Hepatic impairment

The effect of hepatic impairment on the pharmacokinetics of melatonin administered has not been studied. Published data show elevated endogenous melatonin levels in patients with hepatic impairment. Since melatonin is largely eliminated via liver metabolism, exposure to melatonin is likely to be higher in patients with hepatic impairment (see section 4.2).

Elderly

In a comparative study of the levels of serum melatonin with and without administration of exogenous melatonin, lower concentrations were found in moderately older adults without treatment, while a trend toward higher concentrations was observed compared to healthy younger adults after treatment. The observed difference between the age groups was not statistically significant. The same dose of melatonin can be recommended to older adults and younger adults.

5.3 Preclinical safety data

Current studies on safety pharmacology, general toxicity, genotoxicity and carcinogenicity, did not show any particular risks to humans.

In toxicological studies, effects were seen only at high exposures / at exposures significantly higher than clinical exposures. These effects are therefore considered to have no clinical relevance.

In the reproductive toxicology studies, oral administration of melatonin to pregnant female rats did not lead to any effects on the offspring, with regard to fetal survival, skeletal and visceral anomalies or birth weight. Administration of melatonin to mice early in their pregnancy did not generate any apparent reproductive toxicities.

There are no safety studies in juvenile animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Glycerol (E422) Sorbic acid

Methyl parahydroxybenzoate (E218)

Sodium hydroxide (for pH adjustment)

Water, purified

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

18 months. Shelf life after first opening: 6 months.

6.4 Special precautions for storage

Do not store above 30°C. Store in original bottle in order to protect from light.

6.5 Nature and contents of container

Amber glass bottle 30 ml, 100 ml or 150 ml, with a child-resistant white polypropylene/polyethylene cap with an integrated syringe adapter (30 ml, 100 ml and 150 ml). An oral syringe is packed together with the bottle. The capacity of the syringe is 5 ml with scale graduation of 0.2 ml.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

<[To be completed nationally]>

{Name and address}

8. MARKETING AUTHORISATION NUMBER(S)

<[To be completed nationally]>

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: [To be completed nationally]

10. DATE OF REVISION OF THE TEXT

2025-11-14